Skip to main content
. 2019 Oct 8;12(1):72–85. doi: 10.4168/aair.2020.12.1.72

Table 5. Comorbidities according to AR classifications: comparison between mild, moderate to severe, intermittent and persistent AR.

Comorbidities of AR Mild vs. moderate to severe Intermittent vs. persistent
Mild Moderate to severe Intermittent Persistent
No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI) No./total No. (%) aOR* (95% CI)
Current asthma 9/223 (4.0) 1 (reference) 9/53 (17.0) 5.26 (1.77–15.62) 13/196 (6.6) 1 (reference) 5/80 (6.2) 0.70 (0.22–2.19)
PC20 < 8 mg/mL 37/198 (18.7) 1 (reference) 15/48 (31.3) 2.32 (1.01–5.32) 37/169 (21.9) 1 (reference) 15/77 (19.5) 0.80 (0.37–1.72)
BHR without current asthma 33/194 (17.0) 1 (reference) 10/43 (23.3) 1.64 (0.65–4.15) 30/162 (18.5) 1 (reference) 13/75 (17.3) 0.93 (0.42–2.07)
Current eczema 48/107 (44.9) 1 (reference) 11/26 (42.3) 1.37 (0.42–4.46) 46/102 (45.1) 1 (reference) 13/31 (41.9) 0.81 (0.27–2.44)
Allergic sensitization 101/213 (47.4) 1 (reference) 29/47 (61.7) 1.59 (0.77–3.28) 84/183 (45.9) 1 (reference) 31/46 (59.7) 1.83 (0.98–3.42)

AR, allergic rhinitis; aOR, adjusted odds ratio; CI, confidence interval; BHR, bronchial hyperresponsiveness.

*Adjusted by sex, maternal education levels, parental history of allergic diseases, history of second-hand smoking, residential area, and economic status; P < 0.05; P < 0.01.